Danicopan
Drug Details
- Generic Name
- Danicopan
- Brand Names
- Voydeya
- Application Number
- NDA218037
- Sponsor
- Alexion Pharmaceuticals Inc.
- NDC Codes
- 3
- Dosage Forms
- KIT, TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- DANICOPAN
Indications and Usage
1 INDICATIONS AND USAGE VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). VOYDEYA is a complement factor D inhibitor indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) ( 1 ). Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab. Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab.